Biovian to Attend BioTrinity 2013

Turku-based, Biovian has announced it is to attend BioTrinity 2013 at Newbury Racecourse from 14th -16th May 2013.

By drawing together Europe’s R&D companies with big pharma and biomedical investors, BioTrinity is considered to be Europe’s premier biopartnering and Investment Conference. Biovian’s attendance signals the company’s interest in collaborating with others within the pharmaceutical industry.

“We are looking forward to attending BioTrinity, not just because it gives us the opportunity to meet with existing partners but we’re also seeking new business relationships” commented Biovian’s CEO Dr. Knut Ringbom.

About Biovian
Biovian is a one-stop-shop CMO for GMP manufacture and development of biopharmaceuticals. Biovian offers services from early development to finished vial. Biovian’s 2300 m2 facilities are EMA and FDA certified for cGMP production of investigational and commercial products. The company has a successful ten-year track record in pharmaceutical contract manufacturing.

About BioTrinity
The annual BioTrinity is Europe’s premier event for bringing together R&D companies with investors. Typically, the event attracts around 800 delegates from 500 companies based in 26 countries along with 80 investors from 10 countries. Throughout the event, there are seminars which will see 130 professionals take to the stage to deliver relevant presentations.

For more information or to discuss Biovian attending BioTrinity 2013 please contact Biovian directly.